Category:

Everyday Health, Inc., a…provider of digital health marketing and communications solutions, and Videology, a…software provider for converged TV and video advertising…announced the launch of TVRx, a solution for pharmaceutical and health-oriented marketers to target relevant health audiences across television and digital video. The…partnership combines Everyday Health's…audience reach and analytics…with Videology's…platform for planning, executing and measuring video campaigns across any screen…"Television remains a staple for advertisers in the health vertical. However, as the industry focuses on smaller patient populations and consumer viewing fragments across multiple screens, the ability to reach the right audiences with relevant messaging has become more difficult,"…"TVRx addresses this challenge by enabling advertisers to find the right audience - regardless of viewing screen - and achieve a desired marketing outcome…"TVRx takes everything that is great about TV and incorporates the enhanced targeting and measurement capabilities of digital, to provide the most sophisticated targeting and ROI measurement across both linear TV and digital video.

Take that, Theranos!..Clearly determined to offer direct-to-consumer lab testing through pharmacies, grocery chain Safeway seems to be shaking off the reported demise of a partnership with the not-so-revolutionary-after-all testing company (Theranos)… Sonora Quest Laboratories, a joint venture of Quest Diagnostics and Phoenix’s Banner Health, has opened its first testing center at a Safeway in...Scottsdale, Arizona. A second one will open next week in an upscale part of Phoenix...

Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some ways independent pharmacists could encourage local prescribers to adopt e-prescribing of controlled substances.

A laser-based treatment will allow powdered vaccines to be delivered through the skin, scientists say…A University of Rhode Island researcher is developing an anti-smoking vaccine administered via “a laser-based epidermal skin powder delivery”…The laser platform creates micro-channel arrays – tiny pores – in the skin, through which a powdered vaccine is delivered from a patch applied onto the skin… the system could lead to the first FDA-approved nicotine vaccine, and beyond that, could provide a painless, needle-free alternative to liquid injections…“Generally, vaccines are liquid, but powdered vaccines are more convenient and they have a longer shelf-life,”… The method also allows use of potent nano-encapsuated adjuvants to safely boost skin vaccination without significant local reactions…“This system is expected to safely and profoundly boost nicotine antibody production and completely block nicotine entry into the brain,”

Video technology makes it possible for an urban specialist to see rural patients without anyone having to drive, but it doesn't solve a key underlying issue: there aren’t enough specialists in Nevada…a liver specialist in New Mexico posed this question: What if we used teleconferencing to train primary physicians in rural counties?...The result was Project ECHO, which created a model for other rural health programs in the country, including Nevada in 2012. The local Project ECHO program is run out of the University of Nevada, Reno. According to director Dr. Evan Klass, the program is helping to address doctor shortages…Next up? An expansion into Nevada's urban health centers, which Klass says tend to need just as much help as their rural counterparts these days.

Hundreds of genetically modified mosquitoes that are incapable of spreading the malaria parasite to humans have been created in a laboratory as part of a radical approach to combating the disease…The move marks a major step towards the development of a powerful and controversial technology called a “gene drive” that aims to tackle the disease by forcing anti-malarial genes into swarms of wild mosquitoes…mosquitoes were engineered to carry genes for antibodies that target the human malaria parasite...When released into the wild, researchers believe the modified insects will breed with normal mosquitoes and pass the anti-malarial genes on to their young, making an ever-increasing proportion of future generations resistant to the malaria parasite…To track which insects inherited the antibody genes, the scientists added a tracer gene that gave carriers red fluorescent eyes…Concern that drug and insecticide resistance are eroding recent successes in managing malaria has drawn attention to alternative approaches, including the use of genetically modified mosquitoes.

…many seniors are facing sharply higher premiums for Medicare's popular prescription drug program (Part D). The reason: rising drug costs have overtaken a long stretch of stable premiums…"Premiums are going up. Deductibles are going up,"…Government spending on the program also has risen significantly, driven by pricey new drugs, notably for hepatitis C infection. The cost for the hepatitis drugs in the Medicare program is expected to be $9.2 billion this year, a near doubling from 2014. Because of the prescription program's financial structure, taxpayers cover most of the cost for expensive medications. Three out of four adults infected with hepatitis C are baby boomers…Indicators signal rising costs across the program. Among them:

• independent estimates…show increasing premiums for stand-alone drug plans. The average premium will rise from $36.68 to $41.46 per month next year, or 13 percent…biggest increase since 2009.
• maximum deductible for prescription coverage will rise by $40, to $360…biggest increase in the deductible since the inception of Part D in 2006.
• taxpayer expenditures for the "catastrophic" portion of the benefit - in which beneficiaries with high drug bills pay only 5 percent of the cost - will rise by $4.5 billion in 2016, an increase of more than 14 percent. Spending for catastrophic coverage has doubled in just a short time, from $15.5 billion in 2012 to an estimated $31.2 billion this year.

The analyses...seemingly at odds with the message coming from the Obama administration, which estimates that drug premiums will remain stable in 2016, averaging $32.50 a month.

New data show the staggering reach of the prescription drug epidemic...Doctors wrote 259 million opioid prescriptions for Americans in 2012, enough to medicate every adult in the country. Drug overdoses are eclipsing car crashes as a leading cause of accidental death for American adults…A poll out today from the Kaiser Family Foundation adds a troubling new number to the accounting: 27 percent of Americans report that they either have been addicted to prescription painkillers or have a family member or close friend who has…That's roughly 66 million U.S. adults for whom the opioid crisis has become intensely personal…Prescription drug addiction and a related heroin epidemic have proven a stubborn public health crisis since painkiller abuse began rising more than a decade ago…Kaiser's poll found strong majorities in support of policy solutions, including drug treatment, tighter scrutiny of prescribers, and "good samaritan" laws that protect drug users from being charged if they call for help when addicts overdose.

Treating hepatitis C with expensive new medicines at the earliest signs of liver damage improves patients' health and is also cost-effective, a new computer simulation suggests…"Going into this, I expected to find it did make sense to wait until there was a limited amount of liver disease, but what we found to our surprise is that it makes sense to start treatment at the earliest change in the liver,"…researchers created a simulated model to study the cost-effectiveness of a medicine…The imaginary subjects…of varying ages and with various stages of liver damage… While treating all stages of liver disease was cost-effective, the up-front cost is substantial. Treating half of those with hepatitis C would cost about $53 billion. That cost can be brought down if the price of the drug also decreases, the researchers write…"I think a key policy point here is that cost-effectiveness is important and this study shows that, but a next and important step is...to address the cost of the drug,"

As World Antibiotics Awareness Week draws attention to the threat of resistance, pharma companies large and small say a worldwide overhaul of payment models will make anti-infective R&D profitable again…AstraZeneca published an open letter…calling on the UK government to attract companies to antibiotics discovery work with a more profitable funding mechanism…the pharma industry has been reluctant to sink funds into what it perceives as a poor return on investment. Traditional payment models – where companies profit per volume sold – are a weak incentive in an area where prescription levels are deliberately limited to prevent resistance…Documents so far suggest a shared pot funded by countries – possibly the G20 – “to establish a mechanism to purchase the global sales rights to new antibiotics, and to subsequently manage their supply internationally.“The development and manufacture of drugs would still take place within the pharmaceutical industry, drawn through the pipeline by the incentive of a full ‘buyout’ of their product once it is ready to market. Although the developer would surrender the right to market their new drug, they would be reimbursed by an amount sufficient to ensure an adequate return on their development costs, and the investment incurred.”